M. Qian
5 Papers
M. Qian is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
Toshihiko Doi,M.R. Patel,Gs. Falchook,Takafumi Koyama,Claire F. Friedman,Sarina Anne Piha-Paul,M. Gutierrez,Raghad M Abdul-Karim,M Awad,Douglas Adkins,J. Takahashi,Shigenori Kadowaki,Benjamin Cheng,Nobumasa Ikeda,A. Laadem,Naoto Yoshizuka,M. Qian,O. J. Dosunmu,Hendrik-Tobias Arkenau,M.L. Johnson +19 more
TL;DR: DS-7300 as discussed by the authors is a B7-H3-directed ADC with a topoisomerase I inhibitor payload (DXd), which showed that it was generally well tolerated with early signs of antitumor activity.
25
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy,Yan Chen,Peter Countryman,Bartosz Chmielowski,Stephen P. Anthony,John H. Healey,O. Wainberg,Allen Lee Cohn,B. Shapiro,Vicki L. Keedy,Arun D. Singh,Igor Puzanov,Andrew J. Wagner,M. Qian,Michael N. Sterba,Henry H. Hsu,Sandra Tong-Starksen,William D. Tap +17 more
TL;DR: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT.
6
Treatment of Candida albicans liver abscess complicated with COVID-19 after liver metastasis ablation: A case report
TL;DR: In this article , the authors reviewed the mechanism of ferroptosis and the progress in the treatment of esophageal cancer (EC) and further elaborate the interaction between the mechanism and immunotherapy.
1
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.
A. Wagner,William D. Tap,S. Bauer,Jean-Yves Blay,Jayesh Desai,H. Gelderblom,E. Palmerini,Christopher W Ryan,Charles Peterfy,John H. Healey,Michiel A. J. van de Sande,M. Qian,Dale E. Shuster,A. Rajper,K. Tecson,Margaret J Wooddell,Silvia Stacchiotti +16 more
DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.
Manesh R. Patel,Melissa Lynne Johnson,Gerald S. Falchook,Toshihiko Doi,Claire F. Friedman,Sarina Anne Piha-Paul,Martin Gutierrez,T. Shimizu,Benjamin Cheng,M. Qian,Xia Qian,Yusuke Myobatake,Abderrahmane Laadem,Naoto Yoshizuka,Tracey Hammett,Julius Kirui,Hendrik-Tobias Arkenau +16 more
TL;DR: Preliminary data indicate improvements in prostate-specific antigen (PSA) and bone metastases and the safety and efficacy of DS-7300 was well tolerated with an acceptable safety profile in pts with mCRPC.